why choose us

First received: May 18, 2023

Clinical Trial: A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Primary Malignant Brain Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics &Preliminary Anti-Cancer Efficacy of ABM-1310 in Patients With BRAF V600-Mutant Relapsed &a

Brief Summary: Overall Design: This is a phase I, open-label, multicenter clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer efficacy of ABM-1310 in patients with BRAF V600-mutant relapsed and drug resistant primary malignant brain tumors.The study including four periods of screening (28 days), treatment (no more than 2 years), safety follow-up and survival follow-up.This study consists of two stages: dose escalation and dose expansion.During the dose escalation stage, a classic…

Read more